Cargando…

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease

There have been no robust data from clinical trials to guide the clinician in the choice of therapeutic agents for the child with intravenous immunoglobulin (IVIG) resistance. The treatment regimen for IVIG-resistant patients varies between institutions, and the best option has not yet been establis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhouping, Chen, Feiyan, Wang, Yanfei, Li, Wei, Xie, Xiaofei, Liu, Peiying, Zhang, Xu, Zhang, Li, Huang, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707959/ https://www.ncbi.nlm.nih.gov/pubmed/33299898 http://dx.doi.org/10.1155/2020/4175821

Ejemplares similares

Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients
por: Wang, Zhouping, et al.
Publicado: (2020)

Correlation between the Level of Inflammatory Cytokines and Prognosis in Children with IVIG-sensitive Kawasaki Disease and IVIG-resistant Kawasaki Disease
por: Zhang, Hao, et al.
Publicado: (2022)

A Comparative Study of IVIG versus IVIG with IV Methylprednisolone in Guillain–Barre Syndrome
por: Bhattiprolu, Rahi Kiran, et al.
Publicado: (2020)

Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study
por: Cai, Jiang Hui, et al.
Publicado: (2022)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease
por: Zhang, Rui Long, et al.
Publicado: (2020)

Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection
por: Dionne, Audrey, et al.
Publicado: (2018)

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease
por: Han, Ji Whan
Publicado: (2017)

Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment
por: Chen, Zhen, et al.
Publicado: (2023)

Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)
por: Zhang, Wei, et al.
Publicado: (2023)

Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review
por: Crayne, Courtney B., et al.
Publicado: (2019)

Chronic, eventually fatal, Kawasaki-like disease in an adult with spondylarthropathy responding to IVIG therapy
por: Soltner, Elise, et al.
Publicado: (2009)

Treatment of scleromyxedema with IVIg
por: Moser, David W, et al.
Publicado: (2012)

Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study
por: Zhu, Xiao-Lu, et al.
Publicado: (2022)

DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease
por: Portman, Michael A, et al.
Publicado: (2013)

Cooling down VITT with IVIG
por: Lentz, Steven R.
Publicado: (2021)

A Case of Kawasaki Disease with Coronary Aneurysm Responding to the 4th IVIG Treatment
por: Kim, Ju Young, et al.
Publicado: (2014)

An Update on Reports of Atypical Presentations of Kawasaki Disease and the Recognition of IVIG Non-Responder Children
por: Conte, Cristiano, et al.
Publicado: (2023)

Clinical characteristics and correlation analysis of IVIG resistance in children with kawasaki disease complicated with hip synovitis: case-control study
por: Wang, Jianjie, et al.
Publicado: (2023)

Eczematous reaction to IVIG for the treatment of dermatomyositis()()
por: Berk-Krauss, J., et al.
Publicado: (2018)

Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease
por: Inoue, Takashi, et al.
Publicado: (2020)

Tenascin-C predicts IVIG non-responsiveness and coronary artery lesions in kawasaki disease in a Chinese cohort
por: Li, Yujie, et al.
Publicado: (2022)

PTX3 promotes IVIG resistance-induced endothelial injury in Kawasaki disease by regulating the NF-κB pathway
por: Sun, Ye, et al.
Publicado: (2023)

Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease
por: Kitoh, Toshiyuki, et al.
Publicado: (2021)

The Associated of the Risk of IVIG Resistance in Kawasaki Disease with ZNF112 Gene and ZNF180 Gene in a Southern Chinese Population
por: Lu, Zhaojin, et al.
Publicado: (2022)

An antivenin resistant, IVIg-corticosteroids responsive viper induced thrombocytopenia
por: Turetta, Matteo, et al.
Publicado: (2022)

Decreased Steroid Hormone Receptor NR4A2 Expression in Kawasaki Disease Before IVIG Treatment
por: Huang, Ying-Hsien, et al.
Publicado: (2019)

Major methylation alterations on the CpG markers of inflammatory immune associated genes after IVIG treatment in Kawasaki disease
por: Li, Sung-Chou, et al.
Publicado: (2016)

Clinical implications of procalcitonin in Kawasaki disease: a useful candidate for differentiating from sepsis and evaluating IVIG responsiveness
por: Niu, Man Man, et al.
Publicado: (2021)

IVIG Treatment and Prognosis in Guillain–Barré Syndrome
por: van Doorn, Pieter A., et al.
Publicado: (2010)

IVIG Effects on Erythrocyte Sedimentation Rate in Children
por: Salehzadeh, Farhad, et al.
Publicado: (2014)

Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
por: De Groot, Anne S., et al.
Publicado: (2013)

IVIG regulates the survival of human but not mouse neutrophils
por: Schneider, Christoph, et al.
Publicado: (2017)

Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations
por: Hooper, John A.
Publicado: (2008)

Unraveling the mechanisms of IVIG immunotherapy in MIS-C
por: Ganigara, Madhusudan, et al.
Publicado: (2021)

Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
por: DeBiasi, Roberta L.
Publicado: (2021)

MIS-C Treatment: Is IVIG Always Necessary?
por: Licciardi, Francesco, et al.
Publicado: (2021)

Tubulointerstitial nephritis complicating IVIG therapy for X-linked agammaglobulinemia
por: Sugimoto, Keisuke, et al.
Publicado: (2014)

2031. False-positive Serologic Results attributable to IVIG therapy
por: Hanson, Kimberly E, et al.
Publicado: (2018)

The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease
por: Samadli, Sama, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7lq9ldpvfne0nola7qoums0fml